资源描述：
《阿德福韦酯与拉米夫定治疗慢性乙型肝炎对比分析》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。
1、阿德福韦酯与拉米夫定治疗慢性乙型肝炎对比分析 [摘要]目的比较阿德福韦酯（贺维力）与拉米夫定（贺普丁）治疗慢性活动性乙型肝炎的临床疗效，以提高有效率，减少耐药性。方法收集我院2008年12月~2011年1月经消化内科应用上述两种药物系统治疗慢性活动性乙型肝炎患者150例，根据用药分为三组各50例：分别为使用贺维力、贺普丁及两种药物合用。分别于治疗的12、24、36、52周观察HBV-DNA病毒复制情况及ALT阴转率，比较各组间患者的临床疗效。结果贺维力组连续治疗52周，各时期HBV-DNA转阴率分别为32.0%、
2、54.0%、62.0%、74.0%；贺普丁组分别为48.0%、52.0%、52.0%、66.0%；联合用药组分别为48.0%、54.0%、68.0%、78.0%。经过贺维力组连续治疗52周，各时期ALT转阴率分别为30.0%、44.0%、76.0%、70.0%；贺普丁组分别为60.0%、68.0%、80.0%、72.0%；联合用药组分别为62.0%、66.0%、74.0%、74.0%。结论治疗52周时，贺维力组HBV-DNA及ALT转阴率略好于贺普丁组，与联合用药组无明显差异。 [关键词]贺维力；贺普丁；慢性活动
3、性乙型肝炎 [中图分类号]R512.6+2[文献标识码]B[文章编号]1673-9701（2011）33-46-02 ComparativeStudyofAdefovirDipivoxilandLamivudineintheTreatmentofChronicHepatitisB QULichun1ZHAOHai2ZHAOHongran3LANLan1 1.MRIRoom,DaqingOilFieldGeneralHospital,Daqing163001,China;2.DepartmentofRad
4、iology,DaqingRanghuluRailwayHospital,Daqing163712,China;3.MedicalDeviceDivision,DaqingRanghuluRailwayHospital,Daqing163712,China [Abstract]ObjectiveTocomparethepowerofAdefovirdipivoxilandLamivudineinthetreatmentofchronicactivehepatitisBclinicalefficacy,soas
5、toimproveefficiency.MethodsAllof150caseswerecollectedwhichweretreatedbytwodrugswementionedinourhospitalfromDesember2008toJanury2011.Allcasesinthreegroupsaccordingthetreatment:group1:AdefovirDipivoxil;group2:Lamivudine;Group3:twodrugscombinationused,50casesresp
6、ectively.inthetreatmentof12weeks,24weeks,36weeks,52weeksobservedHBV-DNAviralreplicationandALTnegativerate,comparingtheclinicalefficacybetweeneverytwogroups,andanalysistheresult.ResultsAfter52weekstreatment,ingroup1theHBV-DNAnegativerateswere32.0%,54.0%,62.0%,7
7、4.0%;ingroup2:48.0%,52.0%,52.0%,66.0%;ingroup3:48.0%,54.0%,68.0%,78.0%.AftercontinuoustreatmentbyAdefovirDipivoxilfor52weeks,theALTnegativerateswere,1:30.0%,44.0%,76.0%,70.0%;group2:60.0%,68.0%,80.0%,72.0%;group3:62.0%,66.0%,74.0%,74.0%.ConclusionAfter52weekst
8、reatmentbythedrugofgroup1,thenegativeratioofHBV-DNAandALTslightlybetterthangroup2,withnosignificantdifferenceinthegroup3. [Keywords]Adefovirdipivoxil;Lamivudine;Chronicactivehepat
